A new study reveals that the current breast cancer screening guidelines miss 95% of women under 50 who are at risk. While routine mammogram checks are offered to women over 50, the criteria set by the National Institute of Health and Care Excellence (NICE) mainly focus on genetic factors, overlooking other crucial aspects like lifestyle. Consequently, women under 50 are often excluded from breast screenings unless they have a strong family history of the disease.
To address this gap, a new risk assessment tool called Boadicea, developed by Cambridge and funded by Cancer Research UK, takes into account various factors such as family history, lifestyle choices, reproductive history, and genetic information. This comprehensive approach identified eight times more women under 50 who are likely to develop breast cancer compared to the current guidelines.
Experts emphasize that the existing NICE criteria fail to identify the majority of younger women who will develop breast cancer within the next decade, prompting calls for a reevaluation of the screening criteria. Breast cancer, a prevalent form of cancer globally, affects about one in four cancer cases and is a leading cause of death among women under 50 in the UK. Shockingly, only 5-10% of cases are linked to inherited genes, with 73% of affected women under 50 having no family history of the disease.
Analysis suggests that the criteria provided to general practitioners in England miss up to 95% of women under 50 who could potentially develop breast cancer within ten years, including those with higher-than-average risk. Early identification of high-risk individuals is crucial for early intervention and better outcomes in managing or preventing breast cancer.
Dr. Juliet Usher-Smith from the University of Cambridge highlights the urgency to improve the identification of women at highest risk to enhance treatment and prevention strategies. Similarly, Professor Montserrat García-Closas from the ICR acknowledges the challenge of balancing the practicality and resource implications of a full risk assessment, including genetic testing.
Dr. Simon Vincent, Chief Scientific Officer at Breast Cancer Now, stresses the limitations of the current NICE referral criteria and advocates for incorporating the latest research into the revision of family history guidelines. Moreover, ensuring adequate investment in family history services within the NHS is essential for effective implementation of any potential changes.
While NICE appreciates the findings of the study and the potential of multifactorial risk models in enhancing breast cancer risk identification, they maintain that the current evidence does not warrant an immediate change to the existing familial breast cancer guideline. NICE remains committed to reviewing new evidence and considering updates as more data on feasibility and clinical outcomes become available.
